**Divi’s Laboratories Reports Earnings Below Expectations Amid Pricing Pressures**
Divi’s Laboratories Ltd, a prominent contract development and manufacturing organization (CDMO), reported its earnings for the June quarter, which fell short of market expectations primarily due to pricing pressures in its generics segment. The Hyderabad-based pharmaceutical company saw its operational revenue increase by 13.7% year-on-year, reaching ₹2,410 crore, while its net profit surged by 26.7% to ₹545 crore. On a standalone basis, the net profit for the first quarter of the fiscal year 2025-26 was recorded at ₹557 crore.
Analysts from a Bloomberg poll of 18 brokerages had anticipated revenue of ₹2,462 crore and a net profit of ₹582.7 crore. The company’s EBITDA (earnings before interest, taxes, depreciation, and amortization) rose by 17.2% year-on-year to ₹729 crore, with the EBITDA margin slightly improving to 30.25% from 29.37% in the previous year. However, brokerages such as Kotak Securities and Nuvama had projected the EBITDA margin to expand to 33-34% for the quarter.
Divi’s generics business accounted for 47% of its total revenue, while the custom synthesis segment contributed the remainder. The company manufactures drugs for both generic and innovative pharmaceutical players. Custom synthesis involves creating specific chemical compounds, including novel active pharmaceutical ingredients (APIs) tailored to client specifications. APIs are essential components that ensure the effectiveness of medications.
The ongoing pricing pressures in global markets, particularly in the United States, have impacted generic drug manufacturers, including Divi’s. Nevertheless, the company’s management expressed confidence during an earnings call, highlighting its resilience due to strong backward integration.
Additionally, Divi’s has experienced heightened interest from global innovators seeking to diversify and mitigate risks in their supply chains, particularly away from China. This trend positions Indian CDMO leaders like Divi’s to benefit from increased requests for proposals. In the last quarter of 2024-25, the company announced a long-term manufacturing and supply agreement with a leading global pharmaceutical firm, for which it is investing between ₹650-750 crore. Earlier this year, Divi’s commenced commercial operations at Unit 3 of its Kakinada facility.
Looking ahead, the company plans to implement three capital expenditure programs with an estimated budget of ₹2,000 crore, as stated by CEO Kiran Divi.
In response to the earnings report, Divi’s Laboratories shares closed at ₹6,183 on the National Stock Exchange, reflecting a decline of 3.53% as the results did not meet market expectations.
**FAQ**
**What factors contributed to Divi’s Laboratories missing earnings estimates?**
Divi’s Laboratories missed earnings estimates primarily due to pricing pressures in its generics business, which affected overall profitability despite a year-on-year increase in revenue and net profit.